NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa – Yahoo Finance
Telegraph.co.uk |
NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa
Yahoo Finance NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announces that the Company has commenced enrolling and dosing subjects in a Phase I/II clinical trial to treat … Blind British man in world's first operation to deliver modified DNA to his eyes |
